Our study focused on examining MHC class I epitope specificities of CD8+ T cells from HGSC patient TILs, in relation to the potentially immunogenic tumor antigens identified from mutated tumor neo-antigens, known over-expressed tumor-antigens, targets of IgG auto-antibody responses, and tumor-presented MAPs. This evidence concerns the gene CD8A and neoplasm.